851435-28-4

Usage

Uses

Used in Pharmaceutical Research and Development:
(2-Chloro-6-methyl-pyrimidin-4-yl)-(5-methyl-3H-pyrazol-3-yl)-amine serves as a key intermediate in the pharmaceutical industry, where it is employed for the synthesis of novel drugs. Its potential biological activity makes it a valuable component in the creation of medications targeting specific health conditions.
Used in Agrochemicals:
In the agrochemical sector, (2-Chloro-6-methyl-pyrimidin-4-yl)-(5-methyl-3H-pyrazol-3-yl)-amine is utilized in the development of new pesticides or herbicides. Its chemical properties allow it to be integrated into formulations that can effectively control or eliminate unwanted plant species or pests, thereby enhancing crop protection and yield.
Used in Chemical Synthesis:
(2-Chloro-6-methyl-pyrimidin-4-yl)-(5-methyl-3H-pyrazol-3-yl)-amine is also used as a versatile building block in organic chemistry for the synthesis of a range of chemical compounds. Its reactivity and structural features facilitate the creation of new molecules with specific functions and applications in various industries.
Used in Academic Research:
(2-Chloro-6-methyl-pyrimidin-4-yl)-(5-methyl-3H-pyrazol-3-yl)-amine is a subject of interest in academic research settings, where scientists investigate its properties, reactivity, and potential applications. Studies on (2-Chloro-6-methyl-pyrimidin-4-yl)-(5-methyl-3H-pyrazol-3-yl)-amine contribute to the broader understanding of chemical compound behavior and can lead to innovative applications in multiple fields.

Upstream product

• 5424-21-5 2,4-dichloro-6-methylpyrimidine 
• 31230-17-8 3-methyl-5-aminopyrazole 
• 31230-17-8 3-amino-5-methylpyrazole 
• 42779-56-6 2,4-dichloro-6-methyl-pyridine 

Relevant academic research and scientific papers

PIPERAZINE AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE

The present invention relates to a piperazine amide derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, and use of same as a therapeutic agent, especially as a selective Rearranged During Transfection (RET) kinase inhibitor. Ring a, ring e, X1, X2, X3, X4, R1, R2, R3, R4, R4', R5, R5', R6, R6', R7, R7', R8, m, and n have the same definitions as those in the specification.

Methylpyrazole derivatives as RET inhibitor

The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.

Nitrogen heterocyclic compound, pharmaceutical composition containing nitrogen heterocyclic compound, and preparation method and application of nitrogen heterocyclic compound

Disclosed are a nitrogen heterocyclic compound represented by a formula (I), a pharmaceutical composition comprising the same, and a preparation method and use of the nitrogen heterocyclic compound, and in particular, relates to the use of the nitrogen heterocyclic compound for prevention or treatment of diseases or conditions associated with RET activity.

Five-membered heterocyclic derivatives as well as preparation method thereof and use thereof in medicine

The invention provides five-membered heterocyclic derivatives or pharmaceutically acceptable salts thereof which are shown in a general formula (I), a preparation method of the five-membered heterocyclic derivatives or the pharmaceutically acceptable salts thereof, and use of the five-membered heterocyclic derivatives or the pharmaceutically acceptable salts thereof as a therapeutic agent, especially as a rearrangement (RET) kinase inhibitor during selective transfection. In the general formula (I), the definitions of A, B, C, D, E, X, R1, R2 and R3 are the same as those in the description. The general formula (I) is described in the description.

SUBSTITUTED CYCLOPENTANE-AMIDES FOR TREATING DISORDERS RELATED TO RET

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET

Described herein are compounds of formula (I) that inhibit wild- type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

INHIBITORS OF RET

Inhibitors of wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

INHIBITORS OF RET

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34

Autophagy is a critical regulator of cellular homeostasis and metabolism. Interference with this process is considered a new approach for the treatment of disease, in particular cancer and neurological disorders. Therefore, novel small-molecule autophagy modulators are in high demand. We describe the discovery of autophinib, a potent autophagy inhibitor with a novel chemotype. Autophinib was identified by means of a phenotypic assay monitoring the formation of autophagy-induced puncta, indicating accumulation of the lipidated cytosolic protein LC3 on the autophagosomal membrane. Target identification and validation revealed that autophinib inhibits autophagy induced by starvation or rapamycin by targeting the lipid kinase VPS34.

2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.